Phil Newman’s Post

🚀 Today we unveiled DLT – the intelligence platform for longevity, and I couldn’t be more excited about what this means for our industry. For years, the longevity ecosystem has been rich in innovation but poor in structured intelligence. Investors, pharma and founders have had to navigate fragmented data, scattered insights and incomplete visibility into what’s really happening across aging science. DLT changes that. We’ve built an AI-native intelligence platform designed to turn longevity into a living, queryable dataset... starting with more than 600 longevity biotech companies. This is a major evolution for Longevity.Technology as we expand from media into a truly data-centric platform supporting the growth of the global longevity sector. DLT Biotech is just the beginning - with clinics, diagnostics and the broader ecosystem coming next. The longevity industry is accelerating, capital is returning and the timing feels right to bring deeper clarity to the space. If you’re a biotech, investor or pharma team and want to see where longevity is heading, I’d love you to explore what we’ve built. 🔗 Check out the full article: https://lnkd.in/ebiiPWep #Longevity #Biotech #AI #Healthspan #Investment #Pharma